DE602007007923D1 - Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide - Google Patents

Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide

Info

Publication number
DE602007007923D1
DE602007007923D1 DE602007007923T DE602007007923T DE602007007923D1 DE 602007007923 D1 DE602007007923 D1 DE 602007007923D1 DE 602007007923 T DE602007007923 T DE 602007007923T DE 602007007923 T DE602007007923 T DE 602007007923T DE 602007007923 D1 DE602007007923 D1 DE 602007007923D1
Authority
DE
Germany
Prior art keywords
therapeutic polypeptides
increasing
vivo recovery
polypeptides
recovery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007007923T
Other languages
English (en)
Inventor
Thomas Weimer
Hubert Metzner
Stefan Schulte
Wiegand Lang
Wilfried Wormsbaecher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of DE602007007923D1 publication Critical patent/DE602007007923D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE602007007923T 2006-04-11 2007-04-02 Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide Active DE602007007923D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06007552 2006-04-11
PCT/EP2007/002948 WO2007115724A2 (de) 2006-04-11 2007-04-02 Method of increasing the in vivo recovery of therapeutic polypeptides

Publications (1)

Publication Number Publication Date
DE602007007923D1 true DE602007007923D1 (de) 2010-09-02

Family

ID=36778259

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007007923T Active DE602007007923D1 (de) 2006-04-11 2007-04-02 Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide

Country Status (12)

Country Link
US (3) US20100222554A1 (de)
EP (2) EP2263696A1 (de)
JP (1) JP2009533364A (de)
KR (1) KR101492422B1 (de)
AT (1) ATE474917T1 (de)
AU (1) AU2007236280B2 (de)
CA (1) CA2649199C (de)
DE (1) DE602007007923D1 (de)
DK (1) DK2007885T3 (de)
ES (1) ES2349024T3 (de)
PL (1) PL2007885T3 (de)
WO (1) WO2007115724A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1816201A1 (de) * 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
AU2007338298B2 (en) 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
EP2209487A4 (de) * 2007-10-15 2012-06-20 Univ North Carolina Varianten von humanem faktor ix mit verlängerter halbwertszeit
KR20120061898A (ko) * 2009-08-20 2012-06-13 체에스엘 베링 게엠베하 출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자
KR20140017480A (ko) 2010-07-09 2014-02-11 바이오겐 이데크 헤모필리아 인코포레이티드 인자 iｘ 폴리펩티드 및 이들의 사용 방법
HUE039070T2 (hu) * 2010-11-22 2018-12-28 Amicus Therapeutics Inc Új szignálszekvenciák fehérje-expresszió és rekombináns enzimek és más fehérjék szekréciójának javítására
TWI750197B (zh) * 2012-09-25 2021-12-21 美商百歐維拉提夫治療公司 Ｆｉｘ多肽的應用
SG10201707600XA (en) 2013-03-15 2017-11-29 Biogen Ma Inc Factor ix polypeptide formulations
AU2019359385A1 (en) 2018-10-10 2021-05-13 Amicus Therapeutics, Inc. Disulfide bond stabilized polypeptide compositions and methods of use
US20210379203A1 (en) * 2018-10-26 2021-12-09 Vrije Universiteit Brussel New Tools for Improving Gene Therapy and Use Thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
EP1621206A1 (de) * 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimäre Zytokine und ihre Verwendung
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
JP3735921B2 (ja) * 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 ＧＰＩｂ・脂質複合体およびその用途
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
US6548653B1 (en) * 1998-06-15 2003-04-15 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
IL150692A0 (en) * 2000-02-11 2003-02-12 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
JP2003530847A (ja) * 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
EP1325113B1 (de) * 2000-10-02 2010-04-21 Novo Nordisk Health Care AG Glykoformen von faktor vii
EP1328622A2 (de) * 2000-10-18 2003-07-23 Maxygen Aps Konjugate und varianten von protein c
EP1444986A1 (de) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmazeutische Zusammensetzung zur verbesserten Behandlung von Krankheiten mit verminderter Blutgerinnung
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AU2005243427B2 (en) * 2004-05-04 2010-07-22 Novo Nordisk Health Care Ag O-linked glycoforms of polypeptides and method to manufacture them
EP1816201A1 (de) * 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP1867660A1 (de) * 2006-06-14 2007-12-19 CSL Behring GmbH Fusionsprotein welches proteolytisch geschnitten werden kann und einen Faktor der Blutgerinnungskaskade enthält
AU2007338298B2 (en) * 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life

Also Published As

Publication number Publication date
EP2007885A2 (de) 2008-12-31
KR101492422B1 (ko) 2015-02-12
KR20090008329A (ko) 2009-01-21
CA2649199C (en) 2015-01-20
WO2007115724A3 (de) 2008-03-20
ATE474917T1 (de) 2010-08-15
US20140248686A1 (en) 2014-09-04
AU2007236280B2 (en) 2013-07-25
ES2349024T3 (es) 2010-12-21
EP2263696A1 (de) 2010-12-22
US20130337532A1 (en) 2013-12-19
JP2009533364A (ja) 2009-09-17
PL2007885T3 (pl) 2010-12-31
DK2007885T3 (da) 2010-11-08
EP2007885B1 (de) 2010-07-21
US20100222554A1 (en) 2010-09-02
AU2007236280A1 (en) 2007-10-18
WO2007115724A2 (de) 2007-10-18
CA2649199A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
DE602007007923D1 (de) Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
CL2009001258A1 (es) Polipeptido multivalente que comprende dos dominios de fibronectina tipo iii, ligados por un polipeptido de engarce basado en glicina-serina o glicina-prolina.
CY1122195T1 (el) Πολυπεπτιδια συντηξης σερπινης και μεθοδοι χρησης αυτων
GT200700059A (es) Proteinas de fusion de exendina
SG171670A1 (en) Rage fusion proteins, formulations, and methods of use thereof
MX2008002101A (es) Fusiones de la proteina-1 quimiotactica de monocito.
ATE426174T1 (de) Verfahren zum nachweis der amyloid-beta oligomere in kírperflussigkeiten
NZ703581A (en) Anti-cd70 antibody drug conjugates
HRP20220214T1 (hr) Imunomodulacijska sredstva
UY31123A1 (es) Proteinas de fusion natriureticas
CY1117697T1 (el) Σταθεροποιημενα απο δεσμους δισουλφιδιων λειτουργικα ευδιαλυτα ετεροδιμερη toy mhc ταξης ii
WO2010117760A3 (en) Fusion proteins comprising canine fc portions
EA201290722A1 (ru) Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
IL220164B (en) A method for purifying a purified antibody, antibody fragment, or fc-fused protein using an affinity chromatography matrix
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
MX2014000054A (es) Moleculas de union anti-alfa sinucleina.
IL210175A0 (en) Fn14/trail fusion proteins
HK1125387A1 (en) Compositions and methods for fusion protein separation
ECSP12011577A (es) Produccion recombinante de péptidos
EP2035572A4 (de) Verfahren zur herstellung von faktor-viii-proteinen durch rekombinationsverfahren
MX2013015324A (es) Polipeptidos de fusion con domino de proteína ácida del suero, y métodos de uso de los mismos.
NO20084776L (no) En fremgangsmåte for konsentrasjon av et polypeptid
DE602006015421D1 (de) HER-2/neu Multipeptidimpfstoff
WO2010023670A3 (en) Methods for covalently attaching a polymer to a methionine residue in proteins and peptides
WO2009025300A1 (ja) イミュノグロブリン結合能を有するペプチド